Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  MANAGEMENT DISCUSSION
Management Discussion      
Kobo Biotech Ltd.
BSE Code 531541
ISIN Demat INE881A01015
Book Value -56.34
NSE Code NA
Dividend Yield % 0.00
Market Cap 57.66
P/E 0.00
EPS -2.11
Face Value 10  
Year End: March 2015
 

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

PHARMACEUTICAL INDUSTRY OVERVIEW

The recent spurt in emerging markets has directly impacted the pharmaceutical industry. Rising affordability, enhanced life expectancy and improved standard of living are all providing impetus to the demand for pharmaceuticals. the result of new (and ongoing) research and development activities are yet to show the same flair as their brdecessors, we can be assured that such loss of exclusivities certainly enables new players to enter into the market thereby increasing the potential for sales. with rise labor costs in China are set to change the API landscape. The API industry is expected to witness the rise of second wave emerging markets in countries such as Brazil, Mexico, South Korea and Taiwan. The Taiwanese API producers have gained recognition for high quality and international good manufacturing practices (GMP) compliance.

According to report of, "Global API Market Outlook 2018", in the wake of the above developments, the Global API industry is expected to grow at a CAGR of 9.4% from 2013-2018. The market has been divided into four major geographies which comprise Americas, Asia, Europe and the rest of the world. A list of top countries which will be responsible for the majority of API related activities are US, Italy, Japan, China, India and South Korea.

As a result of the more and more regulatory compliances requirements and escalating R&D costs, fiscal austerity measures introduced by governments across many developed countries in the past few years have brsented tremendous challenges for both innovator and generic drug makers.

INDIAN PHARMACEUTICAL MARKET

The Indian Pharma Market ("IPM") is valued at Rs. 903 billion (IMS, MAT March 2015) and is expected to grow at a CAGR of eleven (11) per cent over the next four years. It continues to be a highly fragmented market with a large number of players sbrad across therapeutic segments.

According to McKinsey report Indian Pharma 2020. The Indian Pharma industry is poised for expansion and is expected to grow to US$55 billion by 2020 High economic growth, rapid urbanisation resulting in lifestyle diseases, increased government spending on healthcare, improved healthcare facilities and healthcare insurance plans are some of the growth drivers for the pharma industry.

Risks and Concerns

With a population exceeding 1.2 billion, India is a major market for healthcare companies. According to statistics from the Pharmaceutical Export Promotion Council (or Pharmexcil) on the India Brand Equity Foundation (or IBEF) website, the domestic pharmaceuticals sector in India is experiencing strong growth. This growth is mainly due to increasing penetration into the rural market, which is still largely untapped.

Although India exports pharmaceutical products to more than 200 countries, the US remains the major importer of pharmaceutical products from India—accounting for approximately one-fourth of India's exports in this sector. The Indian pharmaceutical industry, which was estimated to be worth $12 billion during 2013, is expected to grow to $100 billion over the next decade.

Some of the keys Opportunities available to the Company are as follows:

• Huge outsourcing opportunity in Indian APIs industry

• One of the few Indian players in a fast growing Veterinary segment

• Increased thrust on product partnerships by global pharma companies Some of the keys risks and concerns that are faced by the Company are as follows:

• Competition from other Companies operating in similar segments

• Lack of proper Infrastructure facilities.

• Other key risks related to our business may include loss of key personnel, increased labour costs and uncertainties in terms of regulatory changes

• Unavailability of proper health insurance

Finance

Operational &Financial Performance

Sales: During the year under review, owing to sluggish external factors and various issues at the customers end beyond the control of the Management. The Total income was down from Rs. 5707.04 Lacs to Rs. 2911.48 Lacs during the period of review.

Gross Margin (EBIDTA): During the year under review, the Gross margin (Loss) stood at Rs. 939.77 Lakhs as against Gross margin (Loss) of Rs. 427.05Lakhs.

Net Profit/(Loss) : During the year the Net Loss of the Company stood at Rs. 3,025.60 Lakhs as against 3,257.34 Lakhs loss in the last financial year.

Net-worth: The net-worth of the Company decreased to Rs. 1367.12Lakhs from Rs. 4457.02 Lakhs during the brvious year. The decrease has been primarily on account of loss incurred by the company during the year under review.

Internal Control Systems

The Company has internal control systems in place commensurate with the size and industry it operates in. Its always our endeavor to strictly adheres to the laws, rules and statues of the land, and ensures compliance at all levels and across all divisions and departments. Any concerns raised are immediately address and corrected.

There is a proper definition of roles and responsibilities across the organization to ensure information flow and monitoring. The Audit Committee of the Company reviews the statutory audit reports, the quarterly and annual financial statements and discusses all significant audit observations and follow up actions arising from them.

Human Resource Development and Industrial Relations

Avon's HR function is dedicated to overall growth vision of the Company and continuously works on areas such as recruitment and selection policies, disciplinary procedures, reward/recognition policies, learning and development policies and all round employee development. Avon provides a safe and rewarding environment that attracts and retains a talented team and where employees are engaged in delivering exceptional results to the customers and investors.

Cautionary Statement

Statements in the Management Discussion and Analysis describing the Company's objectives, projections, estimate, expectations may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results could differ materially from those exbrssed or implied. Important factors that could make a difference to the Company's operations include, among others, economic conditions affecting demand/supply and price conditions in the domestic and overseas markets in which the Company operates, changes in the Government regulations, tax laws and other statutes and incidental factors.

Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.